Rafael Holdings
Clinical-stage biotechnology holding company investing in and developing oncology therapeutics with a focus on cancer metabolism and novel drug-delivery formulations. Operates multiple clinical programs including late-stage trials, holds majority interests in portfolio biotech subsidiaries (including a company developing PEGylated liposomal prodrug formulations), and maintains commercial real estate assets as part of its investment portfolio.
Industries
Nr. of Employees
small (1-50)
Rafael Holdings
520 Broad Street, Newark, NJ 07102
Products
Development-stage metabolic-targeting oncology compound (lead clinical candidate)
Clinical-stage oncology candidate that targets metabolic enzymes implicated in cancer cell energy production; has been evaluated in multiple clinical trial phases.
PEGylated liposomal prodrug formulation for mitomycin C (development-stage)
A PEGylated liposomal prodrug approach intended to enhance delivery and therapeutic impact of mitomycin C, including targeted formulations for specific indications.
Development-stage metabolic-targeting oncology compound (lead clinical candidate)
Clinical-stage oncology candidate that targets metabolic enzymes implicated in cancer cell energy production; has been evaluated in multiple clinical trial phases.
PEGylated liposomal prodrug formulation for mitomycin C (development-stage)
A PEGylated liposomal prodrug approach intended to enhance delivery and therapeutic impact of mitomycin C, including targeted formulations for specific indications.
Services
Equity investments and operational oversight of research-driven oncology and therapeutic companies within a controlled portfolio.
R&D activities supporting discovery and clinical development of oncology therapeutics focused on cancer-specific metabolic pathways.
Development of PEGylated liposomal prodrug and targeted liposomal formulations intended to enhance delivery and efficacy of chemotherapeutic agents.
Equity investments and operational oversight of research-driven oncology and therapeutic companies within a controlled portfolio.
R&D activities supporting discovery and clinical development of oncology therapeutics focused on cancer-specific metabolic pathways.
Development of PEGylated liposomal prodrug and targeted liposomal formulations intended to enhance delivery and efficacy of chemotherapeutic agents.
Expertise Areas
- Clinical trial management
- Cancer metabolism drug discovery
- Liposomal and supramolecular drug-delivery formulation
- Preclinical development and translational research
Key Technologies
- PEGylated liposomal drug delivery
- Supramolecular delivery vehicles
- Targeted metabolic-enzyme inhibition
- Phase I-IV clinical trial methods
News & Updates
Announcement of continuation of a Phase 3 study after review of prespecified 48-week interim data by an independent data monitoring committee.
Announcement of record date and distribution date for the spin-off of Rafael Holdings from its former parent company.
Announcement of continuation of a Phase 3 study after review of prespecified 48-week interim data by an independent data monitoring committee.
Announcement of record date and distribution date for the spin-off of Rafael Holdings from its former parent company.